Metrika

  • citati u SCIndeksu: [1]
  • citati u CrossRef-u:0
  • citati u Google Scholaru:[]
  • posete u poslednjih 30 dana:0
  • preuzimanja u poslednjih 30 dana:0

Sadržaj

članak: 7 od 15  
Back povratak na rezultate
2009, vol. 66, br. 11, str. 876-880
Faktori rizika od pojave metastaza u mozgu kod lokalno odmaklog nemikrocelularnog karcinoma pluća nakon završene hemio-zračne terapije
aKlinički centar Kragujevac, Klinika za pulmologiju
bVojnomedicinska akademija, Klinika za pulmologiju, Beograd
cKlinički centar Srbije, Klinika za pulmologiju, Beograd

e-adresadrmarinapetrovic@yahoo.com
Sažetak
Uvod/Cilj. Dok se terapija za lokalno odmakli nemikrocelularni karcinom pluća (NSCLC) poboljšava, metastaze u mozgu ostaju veliki problem. Cilj ove studije bio je analiza faktora rizika od pojave metastaza u mozgu kod bolesnika sa lokalno odmaklim NSCLC nakon hemio-zračne terapije. Metode. Analizirani su podaci 150 bolesnika sa neresektabilnim IIIA/ IIIB stadijumom NSCLC lečenih kombinovanom hemio i zračnom terapijom. Svi bolesnici bili su bez metastaza u mozgu pre lečenja. Učestalost metastaza u mozgu ispitivana je u zavisnosti od starosti, pola, histološkog tipa, stadijuma bolesti, 'performans' status skale za procenu kvaliteta života bolesnika sa neoplazmom, gubitka telesne težine, hemioterapijskog protokola i redosleda primene. Rezultati. Jednogodišnja i dvogodišnja incidencija moždanih metastaza bila je 19 i 31%. Stadijum IIIB bio je povezan sa visokim rizikom moždanih metastaza (p < 0,004) u odnosu na stadijum IIIA. Histološki, bolesnici sa neskvamocelularnim tumorom izloženi su značajnom riziku od pojave metastaza u mozgu tokom dvogodišnjeg perioda (32%) (p < 0,02). Ispitivanjem terapijskih parametara, jednogodišnji i dvogodišnji rizik od pojave moždanih metastaza kod bolesnika koji su primali hemioterapiju pre radioterapije, iznosio je 27 i 39%, odnosno 15 i 20% kod bolesnika kod kojih radioterapija nije bila odložena (p < 0,03). Multivarijantnom analizom, vreme za hemioterapiju (p < 0,05) i stadijum IIIA u odnosu na IIIB (p < 0,01) bili su statistički značajni. Zaključak. Bolesnici sa stadijumom IIIB neskvamocelularnog karcinomoma i sekvencionalnom hemioterapijom imaju značajno višu stopu moždanih metastaza.
Reference
Agboola, O., Benoit, B., Cross, P., da Silva, V., Esche, B., Lesiuk, H., Gonsalves, C. (1998) Prognostic factors derived from recursive partition analysis (RPA) of Radiation Therapy Oncology Group (RTOG) brain metastases trials applied to surgically resected and irradiated brain metastatic cases. Int J Radiat Oncol Biol Phys, 42(1): 155-9
Andre, F., Grunenwald, D., Pujol, J.L., Girard, P., Dujon, A., Brouchet, L., Brichon, P.Y., Westeel, V., le Chevalier, T. (2001) Patterns of relapse of N2 nonsmall-cell lung carcinoma patients treated with preoperative chemotherapy: Should prophylactic cranial irradiation be reconsidered?. Cancer, 91(12): 2394-400
Arriagada, R., le Chevalier, T., Borie, F., Rivière, A., Chomy, P., Monnet, I., Tardivon, A., Viader, F., Tarayre, M., Benhamou, S. (1995) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. J Natl Cancer Inst, 87(3): 183-90
Aupérin, A., Arriagada, R., Pignon, J.P., le Péchoux, C., Gregor, A., Stephens, R.J. (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. New England Journal of Medicine, 341(7): 476
Ceresoli, G.L., Reni, M., Chiesa, G., Carretta, A., Schipani, S., Passoni, P., Bolognesi, A., Zannini, P., Villa, E. (2002) Brain metastases in locally advanced nonsmall cell lung carcinoma after multimodality treatment: Risk factors analysis. Cancer, 95(3): 605-12
Chen, Y., Okunieff, P. (2004) Radiation and third-generation chemotherapy. Hematol Oncol Clin North Am, 18(1): 55-80
Cox, J.D., Scott, C.B., Byhardt, R.W., Emami, B., Russell, A.H., Fu, K.K., Parliament, M.B., Komaki, R., Gaspar, L.E. (1999) Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys, 43(3): 505-9
Curran, A.J., Scott, C., Langer, C., Komaki, R., Lee, J.S., Hauser, S., i dr. (2000) Phase III comparison of sequential vs concurrent chemoradiation for patients (pts) with unresected stage III non-small cell lung cancer (NSCLC): initial report of Radiation Therapy Oncology Group (RTOG) 9410. Proc Am Soc Clin Oncol, 19: 1891a
Eberhardt, W., Wilke, H., Stuschke, M., Stamatis, G., Harstrick, A., Menker, H. (1997) 249 Preoperative chemotherapy and concurrent chemoradiotherapy based on hyperfractionated accelerated radiation followed by surgery in locally advanced (LAD) inoperable NSCLC stages IIIA and IIIB: The value of PCI. Lung Cancer, 18(1): 65
Furuse, K., Fukuoka, M., Kawahara, M., Nishikawa, H., Takada, Y., Kudoh, S., Katagami, N., Ariyoshi, Y. (1999) Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unresectable stage III non-small-cell lung cancer. J Clin Oncol, 17(9): 2692-9
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., Mckenna, W.G., Byhardt, R. (1997) Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys, 37(4): 745-51
Gaspar, L.E., Chansky, K., Albain, K.S., Vallieres, E., Rusch, V., Crowley, J.J., Livingston, R.B., Gandara, D.R. (2005) Time from treatment to subsequent diagnosis of brain metastases in stage III non-small-cell lung cancer: A retrospective review by the Southwest Oncology Group. J Clin Oncol, 23(13): 2955-61
Girard, N., Mornex, F. (2007) Chemoradiation for locally advanced nonsmall cell lung cancer. Cancer Radiother, 11, (1-2), 67-76, French
Gregor, A., Cull, A., Stephens, R.J., Kirkpatrick, J.A., Yarnold, J.R., Girling, D.J., Macbeth, F.R., Stout, R., Machin, D. (1997) Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: results of a multicentre randomised trial. United Kingdom Coordinating Committee for Cancer Research (UKCCCR) and the European O. Eur J Cancer, 33(11): 1752-8
Jeremić, Branislav., Shibamoto, Y., Acimović, Ljubisa., Milisavljević, Slobodan. (1996) Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin etoposide for stage III non-small-cell lung cancer: A randomized study. Journal of Clinical Oncology, 14(4): 1065-1070
Law, A., Karp, D.D., Dipetrillo, T., Daly, B.T. (2001) Emergence of increased cerebral metastasis after high-dose preoperative radiotherapy with chemotherapy in patients with locally advanced nonsmall cell lung carcinoma. Cancer, 92(1): 160-4
Lee, D.H., Han, J.Y., Cho, K.H., Pyo, H.R., Kim, H.Y., Yoon, S.J. (2005) Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer. Int J Radiat Oncol Biol Phys, 63(4): 1037-44
Mamon, H.J., Yeap, B.Y., Jänne, P.A., Reblando, J., Shrager, S., Jaklitsch, M.T., Mentzer, S., Lukanich, J.M., Sugarbaker, D.J., Baldini, E.H., Berman, S., Skarin, A., Bueno, R. (2005) High risk of brain metastases in surgically staged IIIA non-small-cell lung cancer patients treated with surgery, chemotherapy, and radiation. J Clin Oncol, 23(7): 1530-7
Martins, R.G. (2005) Treatment of locally advanced non-small cell lung cancer with combination of chemotherapy and radiation. Semin Respir Crit Care Med, 26(3): 273-7
Reboul, F.L. (2004) Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data. Hematol Oncol Clin North Am, 18(1): 41-53
Robnett, T.J., Machtay, M., Stevenson, J.P., Algazy, K.M., Hahn, S.M. (2001) Factors affecting the risk of brain metastases after definitive chemoradiation for locally advanced non-small-cell lung carcinoma. J Clin Oncol, 19(5): 1344-9
Ryan, G.F., Ball, D.L., Smith, J.G. (1995) Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys, 31(2): 273-8
Sause, W., Kolesar, P., Taylor, S.I.V., Johnson, D., Livingston, R., Komaki, R., Emami, B., Curran, W., Byhardt, R., Dar, A.R., Turrisi, A. (2000) Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest, 117(2): 358-64
Sheehan, J.P., Sun, M., Kondziolka, D., Flickinger, J., Lunsford, D.L. (2002) Radiosurgery for non-small cell lung carcinoma metastatic to the brain: long-term outcomes and prognostic factors influencing patient survival time and local tumor control. J Neurosurg, 97(6): 1276-81
Stinchcombe, T.E., Fried, D., Morris, D.E., Socinski, M.A. (2006) Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer. Oncologist, 11(7): 809
Vokes, E.E., Gordon, G.S., Rudin, C.M., Mauer, A.M., Watson, S., Krauss, S., Arrieta, R., Golomb, H.M., Hoffman, P.C. (2001) A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. Invest New Drugs, 19(4): 329-33
 

O članku

jezik rada: srpski
vrsta rada: originalan članak
DOI: 10.2298/VSP0911876P
objavljen u SCIndeksu: 24.11.2009.